Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 168: epcoritamab plus R-mini-CHOP versus R-mini-CHOP in elderly frail or unfit patients with untreated diffuse large B-cell lymphoma
2025-524230-25-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of epcoritamab and rituximab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and follicular lymphoma, transformed (t-FL) (2 arms), sponsored by HOVON. Primary endpoints: Complete remission on or after end of treatment and Progression-free survival. Planned start Aug 2026; status: authorised.
02
Drugs
epcoritamabrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma, transformed (t-FL)
Beyond the preview
Go deeper on 2025-524230-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524230-25-00.